Insmed’s Top Brass Cash In With Coordinated Insider Stock Moves

New insider activity at Insmed ( (INSM) ) has taken place on February 4, 2026.

Several top executives at Insmed have recently sold portions of their company stock, collectively unloading 5,188 shares. Chair and CEO William Lewis led the activity by selling 3,009 shares of Insmed stock in a transaction valued at $470,427. Chief Financial Officer Sara Bonstein sold 748 shares for $116,942, while Chief Operating Officer Roger Adsett sold 791 shares totaling $123,530. Rounding out the insider transactions, Chief Legal Officer Michael Alexander Smith sold 640 shares for $100,012. These coordinated insider sales highlight notable profit-taking among Insmed’s leadership team.

Recent Updates on INSM stock

Insmed shares saw active trading over the last 24 hours amid a series of fundamental and sentiment-driven developments. The company updated that its Phase 3 ENCORE trial of ARIKAYCE (ALIS) in frontline MAC lung disease has completed treatment and primary data collection, reinforcing expectations that this late-stage asset could extend ARIKAYCE’s role and long-term revenue durability, though actual results are still pending. This progress, together with Insmed’s upbeat FY25 revenue outlook above consensus, has supported a constructive fundamental view and underpins analysts’ more favorable long‑term models. Barclays initiated coverage as part of a broadly positive stance on biotech, citing sector tailwinds such as perceived undervaluation, anticipated M&A activity, strong fundamentals, and a less aggressive policy focus on drug pricing as reasons for a supportive setup in 2026. Roth Capital’s initiation is driven by its view that Brinsupri can continue to outperform market expectations and that the ENCORE study has a high probability of success, which in its framework could unlock substantial incremental frontline ARIKAYCE revenue. Options markets reflected bullish positioning, with call volume running about twice normal and implied volatility rising ahead of the February 19 earnings date, suggesting traders are positioning for potentially favorable news or volatility catalysts rather than reacting to any single price move in the cash stock reported here.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

The score is held back most by weak profitability and negative operating cash flow, alongside bearish technicals (below key moving averages and negative MACD). These are partially offset by strong commercial and pipeline momentum from the latest earnings call and corporate updates (BRINSUPRI launch traction, raised/beat revenue guidance, and EU approval), while valuation is mixed due to losses and no dividend support.

To see Spark’s full report on INSM stock, click here.

More about Insmed

YTD Price Performance: -9.70%

Average Trading Volume: 3,046,437

Technical Sentiment Signal: Buy

Current Market Cap: $32.84B